Cascadian Therapeutics, Inc. (NASDAQ:CASC) has been assigned a consensus rating of “Hold” from the six brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $7.00.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 19th. ValuEngine cut shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Cantor Fitzgerald restated a “hold” rating and issued a $4.00 target price on shares of Cascadian Therapeutics in a report on Wednesday, May 10th. Finally, Cowen and Company restated a “buy” rating on shares of Cascadian Therapeutics in a report on Tuesday, May 9th.

WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/brokerages-set-cascadian-therapeutics-inc-casc-pt-at-7-00/1516484.html.

Cascadian Therapeutics (CASC) traded up 4.31% during midday trading on Friday, hitting $3.63. 272,261 shares of the company were exchanged. The stock has a 50 day moving average of $3.89 and a 200-day moving average of $4.00. The stock’s market capitalization is $183.51 million. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $10.98.

Cascadian Therapeutics (NASDAQ:CASC) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.06. During the same quarter in the previous year, the firm posted ($1.57) earnings per share. Equities analysts expect that Cascadian Therapeutics will post $5.02 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of CASC. Perkins Capital Management Inc. boosted its position in shares of Cascadian Therapeutics by 6.4% in the first quarter. Perkins Capital Management Inc. now owns 48,129 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 2,887 shares in the last quarter. OxFORD Asset Management LLP boosted its position in shares of Cascadian Therapeutics by 11.8% in the second quarter. OxFORD Asset Management LLP now owns 181,323 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 19,131 shares in the last quarter. GRT Capital Partners L.L.C. boosted its position in shares of Cascadian Therapeutics by 50.5% in the second quarter. GRT Capital Partners L.L.C. now owns 58,109 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 19,500 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Cascadian Therapeutics during the second quarter valued at $104,000. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Cascadian Therapeutics during the first quarter valued at $122,000. Institutional investors and hedge funds own 83.86% of the company’s stock.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.